Bloomberg News

Mazor Advances Most Since October on FDA Approval of System

December 06, 2011

(Updates with closing price in second paragraph.)

Dec. 5 (Bloomberg) -- Mazor Robotics Ltd. rose the most in almost two months after receiving approval from the U.S. Food and Drug Administration for the three dimensional use of its Renaissance system.

Shares in the developer of surgical robots surged 9.3 percent, the most since Oct. 16, to 4.246 shekels at the 4:30 p.m. close in Tel Aviv.

--Editors: Shanthy Nambiar, Claudia Maedler

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Video Game Avenger
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus